176 citations
,
August 2000 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” In this study, cross-sex hormone therapy affected hair growth patterns differently, with estrogen reducing hair growth in male-to-female transsexuals and testosterone increasing it in female-to-male transsexuals; however, male typical hair diameters were not fully reached in the latter group after 12 months.
491 citations
,
July 2000 in “The Journal of Clinical Endocrinology and Metabolism” This study found that the prevalence of polycystic ovary syndrome was 6.5% in a minimally biased sample of Caucasian women from Spain.
94 citations
,
January 2000 in “The Journal of Clinical Endocrinology and Metabolism” This study found that spironolactone, flutamide, and finasteride are similarly effective in reducing hair diameter and Ferriman-Gallwey scores in women with hirsutism over a 6-month treatment period.
216 citations
,
November 1999 in “Fertility and Sterility” This study found that a basal 17-hydroxyprogesterone level is effective for screening nonclassic adrenal hyperplasia in women, with a 4 ng/mL cutoff providing high specificity and positive predictive value.
294 citations
,
August 1999 in “Journal of the American Academy of Dermatology” This study observed that the majority of side effects from laser-assisted hair removal were associated with ruby and alexandrite lasers, particularly in patients with tanned or darker skin types.
113 citations
,
April 1999 in “The Journal of Clinical Endocrinology and Metabolism” This study found that all four treatments—flutamide, finasteride, ketoconazole, and EE-CPA—significantly reduced hirsutism, but EE-CPA and flutamide appeared most effective, with varying effects on androgen levels and side-effect profiles.
633 citations
,
September 1998 in “The Journal of Clinical Endocrinology and Metabolism” This study observed that among a cohort of reproductive-aged women in the U.S., the prevalence of PCOS was about 4.0%, with no significant racial differences between White and Black women.
74 citations
,
December 1995 in “The Journal of Clinical Endocrinology & Metabolism” This study found that treatment with leuprolide plus cyclic estrogen/progestin may lead to a faster and greater improvement in hirsutism compared to a standard oral contraceptive regimen.
132 citations
,
October 1995 in “Journal of the American Academy of Dermatology” This report concludes that the blend method is the most effective electrolysis technique for permanent hair removal, requiring proper technique and preparation such as shaving before treatment to increase efficacy.
52 citations
,
January 1995 in “The Journal of Clinical Endocrinology and Metabolism” This study observed that finasteride and spironolactone both led to a similar significant, but limited, improvement in hirsutism despite their differing effects on androgen levels.
135 citations
,
August 1994 in “Clinical Endocrinology” In this study of women with hirsutism or androgenic alopecia, diverse underlying endocrine disorders including polycystic ovaries and various enzyme deficiencies were detected, often associated with elevated testosterone levels.
157 citations
,
April 1994 in “Clinical endocrinology” Androgens can cause hair growth in some areas and hair loss on the scalp.
23 citations
,
March 1994 in “Fertility and sterility” This study found that oral contraceptives effectively suppressed hyperandrogenemia in most patients with hyperandrogenic-insulin-resistant acanthosis nigricans syndrome, though GnRH-a therapy was beneficial for those not responding initially.
165 citations
,
February 1994 in “Fertility and Sterility” This study found that flutamide was more effective than spironolactone in reducing symptoms of hirsutism and related conditions in premenopausal women, with fewer discontinuations due to side effects.
68 citations
,
May 1991 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” This study found that both cyproterone acetate and spironolactone effectively reduced hair diameter and plasma testosterone levels in hirsute women, with no significant differences between the two treatments.
25 citations
,
August 1989 in “Seminars in reproductive medicine” This article discusses the use of oral contraceptives for treating hyperandrogenism in women, reporting improvement in most patients, especially in reducing new hair growth, but presents no new clinical findings.
80 citations
,
January 1988 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” This study observed that high-dose spironolactone frequently caused metrorrhagia in women with idiopathic hirsutism, leading the authors to suggest lower starting doses or additional hormonal therapy.
20 citations
,
August 1987 in “Journal of steroid biochemistry/Journal of Steroid Biochemistry” This study suggests that Aldactone may be more effective than Diane in reducing hair growth, despite having minimal impact on hormone levels.
46 citations
,
May 1986 in “Seminars in Reproductive Medicine” Testosterone and dihydrotestosterone affect hair growth, and new techniques like the folliculogram help study it, but fully understanding hair growth is still complex.
44 citations
,
June 1985 in “Fertility and sterility” This study suggests that combination drug therapy with spironolactone and either oral contraceptives or dexamethasone effectively manages unresponsive hirsutism, with eight of nine patients achieving satisfactory clinical responses.
142 citations
,
February 1985 in “Fertility and sterility” This study found that spironolactone reduced serum androstenedione and anagen hair shaft diameter in hirsute patients but did not significantly alter unbound testosterone levels, suggesting its effects are primarily peripheral.
183 citations
,
March 1982 in “JAMA” This study reported that spironolactone at 200 mg/day significantly improved facial hair growth in women with hirsutism and showed a sustained reduction in ovarian androgens over one year.
